SlideShare a Scribd company logo
1 of 16
Download to read offline
Why stability studies ?

 Stability is an essential quality attribute for drug products.
 If there is any functionally relevant quality attribute of a drug product that
  changes with time, this evaluation checked by pharmaceutical scientists and
  regulators who quantify drug product stability and shelf life.
 The rate at which drug products degrade varies dramatically. e.g.
  radiopharmaceutical products
 Since the evaluation of the stability of drug product is highly specialized and
  esoteric nature.
 Drug stability concerns about drug product safety , efficacy, and quality, found it
  to appropriate.
 Stability studies is done through the regulatory agencies such as the FDA and the
  HPB (health protection branch )

Functional changes in dosage forms with time
• It may be related to changes in chemical or physical properties of drug and
   excipients, coating materials etc. or it may be related to complex interaction
   between components of dosage form.
• Chemical stability can be assessed similar to above for drugs and excipients.
• For assessments of physical changes to dosage form changes specific to each
   dosage form should be evaluated.

Changes in Mechanical strength
• Storage in humid condition leads to moisture adsorption and so decreased
  mechanical strength of tablet in blister packages.
• The change in mechanical strength can be described as a function of moisture
  sensitivity, moisture permeability, and humidity condition which is used for
  prediction of storage period.

Changes in drug dissolution from tablets and capsule
• Dissolution of a drug substance is very important characteristic for bioavailability
  and it changes on storage
• Changes in melting time of suppositories
• Changes in release rate from polymeric matrix dosage for , including
  microspheres
• Drug leakage from liposomes
• Aggregation in emulsion
• Discoloration
• Moisture adsorption

Effect of changes on drug stability of drug products
• Packaging play an important role in quality maintenance and the resistance of
   packaging material to moisture and light can significantly affect the stability of
   products
•   Protection from light can be achieved using primary and secondary packaging
       made up of light resistant material.
   •   Incorporating oxygen adsorbents such iron powder can reduce the effect of
       oxygen.3

Relevant guidelines
    ICH Q1A(R2): Stability Testing of New Drug
  Substances and Products
    ICH Q1B: Photostability Testing of New Drug
  Substances and Products
    ICH Q1C: Stability Testing of New Dosage Forms
    ICH Q5C: Stability Testing of Biotechnological/
       Biological Products
    ICH Q1D: Bracketing and Matrixing Designs
    ICH Q1E: Stability Data Evaluation
    ICH Q1F: Stability Data Package for Zones III and IV

Potential adverse effects of instability in pharmaceutical products
There is a various mechanisms by which
drug products may degrade.
    Loss of active
    Increase in concentration of active
    Alteration in bioavailability
    Loss of content uniformity
    Decline of microbiological status
    Loss of content uniformity
    Decline of microbiological status
    Loss of pharmaceutical elegance and patient acceptability
    Formation of toxic degradation products
    Loss of package integrity
    Reduction of label quality
    Modification of any factor of functional relevance. 1

   1. Loss of active
    loss of drug is main significance in the
     stability studies of many pharmaceutical products.
    However, it is certainly true that for many products loss of potency is of major
       importance.
    we regard any product that contains less than 90% of label claim of drug as
       being of unacceptable quality.
    The potency of product stored at the appropriate temperature (250 C for products
       to be labelled “store at controlled room temperature”)
   2. Increase in concentration of active
    For some products, loss of vehicle can result in an increase in the concentration of
       active drug .
    For e.g. lidocaine gels exhibit this behavior
 Perfusion bags sometimes allow solvent to escape and evaporate so that the
  product within the bag shows an increase in concentration.


3. Alteration in bioavailability
 Bioavailability of drug products is a subject of great importance to those
    concerned with drug product quality .
 If the rate or extent of absorption that characterizes a product changes on storage,
    then this of course, a stability problem.
 In particular, if any changes of dissolution test data with time it would effect
    bioavailability
4. Loss of content uniformity
 Suspensions are the drug delivery systems most likely to show a loss of content
    uniformity as function of time.
 For such systems, determination of ease of redispersion or sedimentation volume
    may therefore be included in a stability protocol
5. Decline of microbiological status
 Basically, there are some possible ways in which the microbiological status of a
    pharmaceutical product can change significantly with time.
 The microorganism present in the product at the time of manufacture may
    reproduce and thus increase the number of viable organisms.
 Thus a product that, when assayed for total bioburden at the time of manufacture,
    is within limits, then tested after 6 months storage, exceed the maximum
    permitted bioburden is maximum.
6. Loss of pharmaceutical elegance and patient acceptability
 It includes any aspect of the product that might suggest that the product is
    somehow substandard or variable.
 For example some drugs that contain amino functional groups, when made into
    direct compression tablets that contain spray-dried lactose, which results the some
    slight brown speckling on the surface of the tablet .
 This is due to the interaction of the drug with a minor component in the lactose
 Analysis of the tablets might reveal no loss potency or change in dissolution, but
    no reputable manufacture will market tablets because of its look.
 It is important point about drug products is that attributes such as appearance,
    taste, and smell should be reproducible and not so any significant batch to batch
    variation .
7. Formation of toxic degradation products
 If a drug degrades to a molecular species that is toxic, there must be special
    attention given to the quantity of such a species found in the product during its
    shelf life.
 The classic example is epianhydrotetracycline from tetracycline.
8. Loss of package integrity
 Change in the package integrity during storage or distribution can be a stability
    problem that may require careful monitoring.
 For example, if a plastic screw cap loses back-off –torque, the possibility of
    chemical or microbiological hazard may be significantly increased.
9. Reduction of label quality
    The label of a drug product must be regarded as an essential element of the
       product.
    It provides information on identity, use, and safety. Thus if any aspect of the label
       deteriorates with time, this can be a serious stability problem.
    For example, if the plasticizer in a plastic bottle migrates into the label and causes
       the ink to run and thus effects legibility, this is major problem.
   10. Modification of any factor of functional relevance
    If there is any change of any functionality relevant attribute of a drug product that
       adversely affects safety, efficacy, or patient acceptability.
    For example, when some transdermal patches were first introduce into the US, a
       problem of adhesion ageing is observed .
    Freshly prepared patches show excellent skin adhesion, while it stored in room
       temperature for weeks or months show loss of adhesion.
    Thus in use the patches had a tendency to fall off the patient’s skin 1.

Reasons for stability testing
    Our concerns for patients welfare
    To protect the reputation of the producer
    Requirements of regulatory agencies
    To provide a database that may be of value in the formation of other products
Modes of degradation
Chemical
    Chemical degradation is like solvolysis and oxidation.
    Our knowledge of kinetics can be of material assistance in dealing with chemical
       degradation.
Physical
    Physical degradation can be caused by a
 range of factors such as freezing, thawing, or shearing
    The physical methods that could be used in evaluation of tablet friability,
       suspension redispersibilty, or injection syringeability
Biological
    In north America, Japan, and western Europe it is microbiological stability
       problems.
    However, in some parts of the rats, ants,
 and the non microbiological factors can be responsible for stability problems

Stability indicating method

General tests
    Appearance
    Assays/potency
    Sterility /container integrity
    Moisture
    Degradation products
Product specific tests
   Aggregation (proteins)
   Biological activity (proteins)

Dosage form specific tests
    Dissolution/release rate (tablets/patches)
    Leachable/extractable (injections)
    Particle size and turbidity( injection)
    Preservatives

The essential elements of stability program
    Commitment of the organization to quality
    Firm grasp of underlying scientific theory
    Up-to-date knowledge of all relevant polices of regulatory agencies and
       applicable pharmacopoeial standards
    Effective communication between R&D, production, QC/QA, complaints, and
       regulatory affairs
    Understanding of the limitations of the analytical methods used in the stability
       program
    Careful monitoring of the stability budget
    Managerial skills to coordinate and optimize the program.1

What is kinetics?
   kinetics is a rate of reaction which takes place in a particular compound.
   It may be change in parent compound either physical or chemical.
   Physical change include biotransformation.
   Chemical change include degradation
Application of kinetics in stability
   To understand the mechanism of what kind of change.
   To estimate the degradation time.
   Some time half life or shelf life may be determine by the kinetic.
   For prediction of process mean by keeping the compound, what kind of change
      and how much time will be taken for that change will be estimated.3
Routes by which pharmaceuticals degrade
  a. Chemical degradative routes
  1. Solvolysis
  2. Oxidation
  3. Photolysis
  4. Dehydration
  5. Racemization
  6. Incompatibilities

b. Physical degradative routes
    1. Vaporization
    2. Aging
    3. Adsorption
4. Physical instability in Heterogeneous Systems

Rate of reaction
    Reaction can be of two type
   1. Homogeneous
       this is uniform process and taking place in single phase.
   2. Heterogeneous
       taking place in more than two phase.
   • Eg. decomposition of drug in suspension and enzyme catalyzed reaction.
   • Rate of reaction depended upon concentration of the reactant.
   • Chemical kinetics deals with the experimental determination of reaction rates
       from which rate laws and rate constants are derived.
   • Relatively simple rate laws exist for zero order reactions (for which reaction rates
       are independent of concentration), first order reactions, and second order
       reactions, and can be derived for others.
   • The activation energy for a reaction is experimentally determined through the
       Arrhenius equation and the Eyring equation.

       The main factors that influence the reaction rate include:
   1.   the physical state of the reactants,
   2.   the concentrations of the reactants,
   3.   the temperature at which the reaction occurs, and
   4.   whether or not any catalysts are present in the reaction.

Factors affecting rate of reaction
1. Nature of the Reactants
     Depending upon what substances are reacting, the time varies.
     Acid reactions, the formation of salts, and ion exchange are fast reactions.
     When covalent bond formation takes place between the molecules and when large
       molecules are formed, the reactions tend to be very slow.
2. Physical State
     The physical state (solid, liquid, or gas) of a reactant is also an important factor of
       the rate of change.
     Reaction can only occur at their area of contact, in the case of a liquid and a gas,
       at the surface of the liquid.
     Vigorous shaking and stirring may be needed to bring the reaction to completion.
       This means that the more finely divided a solid or liquid reactant, the greater its
       surface area per unit volume, and the more contact it makes with the other
       reactant, thus the faster the reaction.
3. Concentration
     As the concentration of the reactants increases, the frequency of the molecules
       colliding increases, striking each other more frequently by being in closer contact
       at any given point in time.
     By increasing the amount of one or more of the reactants you cause these
       collisions to happen more often, increasing the reaction rate.
4. Temperature
     Temperature usually has a major effect on the rate of a chemical reaction.
     Collision frequency is greater at higher temperatures, contributes very small
       proportion to the increase in rate of reaction.
     The important factor is reactant molecule should have reactive energy higher then
       activation energy ( E>Ea ) to react.
5. Catalysts
     A catalyst is a substance that accelerates the rate of a chemical reaction but
       remains chemically unchanged afterwards.
     The catalyst increases rate reaction by providing a different reaction mechanism
       to occur with a lower activation energy.
     Proteins that act as catalysts in biochemical reactions are called enzymes.5




    The manner in which the concentration of drug (or reactants) influences the rate
       of reaction or process is called as the order of reaction.
    If C is the conc. of drug A, the rate of decrease in C of drug A as it is changed to
       B can be expressed as a function of time t.
dC/dt = -K Cn
dC/dt = -K Cn _______(1)

K= rate constant
n= order of reaction

If n = 0 than zero order reaction,
If n =1 than first order reaction
dC/dt = term
      Change in conc. (dC) with respect to time (dt) called as rate of reaction

Zero order kinetics
(constant rate processes)
    if n = 0 than,
dC/dt = -K0 C0 = -K0 ____(2)
K0 = zero order rate constant

    It is a reaction whose rate is independent of the concentration of drug undergoing
       reaction, so the rate can’t be increased further by increasing the concentration of
       reactants.
    Rearrangement of equation (2) yields:
dC = -K0 dt
    Integration of above equation:
C – C0 = -K0 t
C = C0 - K0t ______(3)
C = conc. of drug at time t
C0 =conc. of drug at time t = 0
    Eq. 3 states that the conc. of reactant decreases linearly with time.
    A plot of C vs. t yields straight line having slope –K0 and y-intercept C0




                                      C0



          Steady drug loss

                                                Slope = -K0

                                  C
dC/dt




                   time                         time




Zero order half life
    It is the time period req. for the conc. of drug to decrease by one-half.
    When t = t1/2 and C = C0 /2, then eq. 3 becomes
C0/2 = C0 – K0 t1/2
    Solving above eq.
t1/2 = C0/2K0 = 0.5C0/K0 ______(4)

    Eq. shows that t1/2 of a zero order process is not constant but proportional to the
     initial conc. of drug C0 and inversely proportional to the zero order rate constant
     K0. 4

First order kinetics (Linear kinetics)
    If n = 1 then eq. 1 becomes
dC/dt = -K C _____(5)
K = first order rate constant in time-1

    Rate of reaction is directly proportional to the conc. of drug undergoing reaction,
     so greater the conc. , faster the reaction.




                       Slope = -K
     dC/dt




                   C




     Rearrangement of eq. 5 yields
dC/C = -K dt
     Integration of above eq. gives.
ln C = ln C0 – Kt _____(6)
     This eq. can also be written as exponential form as:
C = C0 e-Kt
e = natural log base
     First order process is also known as monoexponential rate process and
        characterized by logarithmic or exponential kinetics.
     Since ln = 2.303 log, eq. 6 can be written as

log C = log C0 – (Kt/2.303) _______(7)

    A semilogarithmic plot of eq. 7 gives a straight line with slope = -K/2.303 and y-
     intercept = log C0
Log C0




                 log C                      Slope = -K/2.303




                                     t1/2



                                              time

                              Semilog graph of first order kinetics




First order half life

     put the value of C = C0/2 at t = t1/2 in eq.7 and solving it
t1/2 = 0.693/K _____(8)
     It indicate that half life of first order reaction is a constant and independent of
        initial drug conc.
     Hydrolytic reaction of many drugs follows second order kinetics but after excess
        amt. of water is added then conc. remain constant throughout the process. It called
        apparent first order kinetics.
SECOND ORDER KINETICS
   If a drug substance A react with a second substance B then:
                                       A+B=C
   Then the rate eq. is
                                  -d[A]/dt = k [A][B]
MIXED ORDER KINETICS (NONLINEAR KINETICS)
   In some cases, the kinetics of a pharmacokinetic process change from predominantly
    first order to predominantly zero order with increasing dose or chronic medication.
   A mixture of both first order and zero order kinetics is called as mixed order kinetics.
    Also known as nonlinear kinetics or dose dependent kinetics.
   Nonlinearity observed in certain drugs like; vitamin C, naproxen, riboflavin. The
    kinetics of such capacity limited processes can be described by the Michaelis-
    Menten kinetics.
   Michaelis Menten Equation

   Mixed order kinetics is best described by this equation:
   -dC/dt = Vmax C/(Km + C) _____(9)

   -dC/dt = rate of decline of drug concentration with time,
   Vmax = theoretical maximum rate of the process,
   Km = Michaelis constant. 4


Factors affecting stability of drug and dosage form
   • These factors can be broadly classified into 3 types depending on their effect on
      different type of stability which are as follows:
   • 1) Chemical factors
   • 2) Physical factors
   • 3) Biological factors

    1) Chemical factors
    Various ways of chemical degradation includes
    • hydrolysis
    • dehydration
    • isomerization & racemization
    • decarboxylation & elimination
    • oxidation
    • photo degradation
    • drug – excipients & drug – drug interactions such as a) Reaction of bisulfite, an
        oxidant
     b) Reaction of amines with reducing sugars3

A) THE ROLE OF MOLECULAR STRUCTURE

    •   It has been noted earlier that molecular structure of drug substance determines its
        degradation mechanisms and that substituents around the reaction centre can
        strongly influence its reactivity.
    •   Example: drug sub. having an electron withdrawing group close to an ester bond
        will probably exhibit a higher propensity nucleophilic attack by hydroxide ion
        than will a similar ester without that functional group
    •   Steric factors can be significant for many chemical reactions.

B) TEMPERATURE
   • It is one of the primary factors affecting drug stability.
   •    The rate constant/temperature relationship has traditionally been described by
     the Arhenius equation,
           k = A exp (-Ea/RT)

    •   where Ea = activation energy
              A = frequency factor
•   Arhenius equation has traditionally been used to describe the temperature
       dependency for various chemical reaction by regarding A and Ea as independent
       of temperature.

   •   Temperature is obviously an important parameter because most reactions proceed
       faster at elevated temperatures than at lower temperatures.

   •   The terms Ea and ∆H are a measure of how sensitive the degradation rate of a
       drug is to temperature changes.

   •  Quantitation of the temperature Dependency of degradation rate constants can be
      done by 3 ways:
   1) Prediction of Degradation rate by Linear Regression Analysis of the Arhenius
      Equation
   2) Prediction of degradation rate by Nonlinear Regression Analysis of the Arhenius
      Equation.
   3) Nonisothermal Prediction of Degradation Rate

C) pH AND pH RATE PROFILES
   • Second most important parameter
   • The effect of pH on degradation rate can be explained by the catalytic effects that
      hydronium or hydroxide ions can have on various chemical reactions.
   • If critical path in a reaction involves a proton transfer or abstraction step, other
      acids and bases present in solution can affect the rate of reaction.
   •   For ionizable drugs, the fraction of drug present in any particular form will
      depend on the pH of the solution,
   • So, if the reactivity of the drug depends on its form, its reactivity will be pH-
      dependent.
   • A reaction in which hydronium ion, hydroxide ion, and water catalysis are
      observed can be described by

                          Kobs = kH+ aH+ + KH2O + KoH- aOH-

    Where Kobs = sum of specific rate constants
            aH+ = activities of hydronium ion
            aOH- =activities of hydroxide ion
This equation is for the case when drug is neutral in the pH range of study.i.e.where the
ionization of drug does not have to take into account

D) BUFFER

   •   These buffer species, like H+ and OH-, participates in formation of break down of
       activated complexes of various reaction and determine their reaction rate.
   •   These catalytic species are referred to as general acid-base catalysts
•   Studies with phosphate buffer indicates that it enhance the degradation of various
      drug substances such as carbenicillin etc.
  •   In addition to acting as proto donor or accepter, buffer species can also act as
      Lewis acid and base through nucleophilic or electrophilic mechanisms.

E) IONIC STRENGTH-PRIMARY SALT EFFECT

  •   For drug degradation involving reactions with or between ionic species, the rate is
      affected by the presence of other ionic species such as salts of NaCl.
  •   Ionic strength affects the observed degradation rate constants, k, by its effect on
      the reactivity coefficients, f.
  •   Ionic strength µ is described by

                  µ = ½ ε Ci Zi2

  Where Ci = conc. Of ionic species I
       Zi =its electric change

  •   As ionic strength increases, the rate of reaction between ions of opposite charge
      decreases and the rate of reaction between ions of similar charges increases.
  •   So, studying the effect of ionic strength can help our understanding of the possible
      charges of the species involved in the degradation.

  F) OXYGEN

  •  Drugs can be affected by the availability of oxygen.
  •  Some photo degradation reactions involve photo oxidative mechanisms that are
     dependent on conc. of oxygen.
  • Oxygen participates as reactant and also alters the degradation rate
  • Oxygen exists in various states such ground state triplate oxygen, etc.
  • Singlate oxygen is highly oxidizing and capable of attacking olfenic bonds.
  • Super oxide species is a mild reductant while hydrogen peroxide is fairly specific
     oxidant.
  G) LIGHT

  •   The number and wavelength of incident photons affect the photo degradation rate
      of drugs.
  •   It is not easy to study the effect of light quantitatively as the wavelength
      dependence of degradation varies among drug substances and because light
      sources have different spectral distributions.
  •   Photo degradation for drug strongly dependence on the spectral properties of the
      drug substances and the spectral distribution of the light source.
H) Crystalline state and polymorphism in solid drugs
• Drugs in the crystalline state have lower ground state free energy and exhibit
   higher ∆G and so, slow reactivity.
• Many drug substances exhibit polymorphism-each crystalline state has a different
   ground state free energy level and a different chemical reactivity.
• The stability of drugs in their amorphous form is generally lower than that of
   drugs

•   In their crystalline form due to higher free energy level of amorphous form.
•   Decreased chemical stability of solid drugs brought about by mechanical stresses
    such as grinding is said to be due to change in crystalline state -eg: grinding of
    aspirin increased degradation rate in suspension form.3

I) MOISTURE AND HUMIDITY

•  Drug degradation in heterogeneous system such as solid and semisolid states is
   affected by moisture.
• Moisture plays important role in catalyzing chemical degradation:
1) Water participates in the drug degradation process itself as a reactant, leading to
hydrolysis; hydration etc. Here degradation rate is directly affected by the
concentration of water, hydronium ion, hydroxide ion.

2) Water absorbs onto the drug surface and forms a moisture-sorbed layer in which
the drug is dissolved and degraded.
• Water adsorption may also change the physical state of the drugs, thereby
    affecting their reactivity.

J) EXCIPIENTS

•   The role that excipients play in drug stability has been extensively reported-e.g.:
    accelerating the effect of talc on hydrolysis of thiamine hydrochloride, the
    accelerating effect of magnesium stearate on tablet containing amines and lactose
    etc.
•   Additional informations include reports on compatibility and incompatibility of
    drugs.
•   Excipients can affect drug stability via various mechanisms.
•   The most obvious examples are those in which the excipients participate directly
    in degradation as reactants.



•   Other mechanisms:

1) Effect of moisture present in excipients
2) The effect pH changes caused by excipients:
3) Effect of surfactants
K) MISCELLANEOUS FACTORS

   •   Effect of γ irradiation:
           − not a common variable
           − employed for sterilization of pharmaceuticals e.g. decreased activity of
               insulin after γ irradiations
   •   Components of pharmaceuticals exist in various physical states like amorphous,
       hydrated and solvated form.
   •   The rate of conversion will depend on chemical potential corresponding to the
       free energy difference between 2 states.

   The various physical changes that can occur in drugs and excipients are as
   follow:

   1) Crystallization of amorphous drugs
   • Attempts are made to formulate poorly soluble drugs into amorphous form as it
       has higher solubility that of crystalline state.
   • But amorphous form change to crystalline state duo low free energy of it.
   • So crystallization of amorphous drug may occur on long storage leading to change
       in release character of drugs and so in its effect.
   • E.g. :amorphous nifedipine co precipitated with polyvinylpyrrolidone, undergoes
       partial crystallization under high humidity conditions resulted altered dissolution
       and solubility

   2) Vapor phase transfers including sublimation
   • Pharmaceuticals containing components that easily sublime may undergo changes
       in drug content due to sublimation of it.
   • E.g. nitroglycerine , which is liquid with significant vapor pressure,sublinguel
       tablet exhibited significant changes in drug content during storage due to inter
       tablet migration through the vapor phase

   3) Moisture Adsorption
   • generally observed with solid pharmaceuticals
   • It leads changes in physical properties such as appearance and dissolution rate.
   • Moisture adsorption is governed by the physical properties of drug and excipients.
   • E.g. :adsorption moisture by aspirin crystals enhanced by addition of hydrophilic
      excipients3

references

   1. Drug stability: principles and practices, 3rd edition, by Jens T. Carstensen and C.
      T. Rhodes
2. Modern pharmaceutics, 4th edition, by Gilbert S. Banker and Christopher T.
   Rhodes
3. Stability of drugs and dosage forms by Sumie Yoshioka and Valentino J. Stella;
   Springer Publication
4. The theory & practice of Industrial Pharmacy by Leon Lachman, 3rd edition
5. www.wikipedia.com

More Related Content

What's hot

Solid state drug stability
Solid state drug stabilitySolid state drug stability
Solid state drug stabilityAnindya Jana
 
Accelerated stability studes
Accelerated stability studesAccelerated stability studes
Accelerated stability studesSunil Boreddy Rx
 
Accelerated stability testing
Accelerated stability testingAccelerated stability testing
Accelerated stability testingMirza Salman Baig
 
Ich guidelines Q1A(R2)
Ich guidelines Q1A(R2)Ich guidelines Q1A(R2)
Ich guidelines Q1A(R2)Surendra Singh
 
Preformulation stability study
Preformulation stability studyPreformulation stability study
Preformulation stability studyArabinda Changmai
 
Stability of Pharmaceuticals
Stability of PharmaceuticalsStability of Pharmaceuticals
Stability of PharmaceuticalsMalay Pandya
 
Stability protocols for different dosage forms by sachin jain
Stability protocols for different dosage forms by sachin jainStability protocols for different dosage forms by sachin jain
Stability protocols for different dosage forms by sachin jainManish Kumar
 
Stability and stability testing
Stability and stability testingStability and stability testing
Stability and stability testingSharon Vijayanand
 
Stability testing and shelf life estimation
Stability testing and shelf life estimationStability testing and shelf life estimation
Stability testing and shelf life estimationManish sharma
 
STABILITY TESTING DURING PRODUCT DEVELOPMENT
STABILITY TESTING DURING PRODUCT DEVELOPMENTSTABILITY TESTING DURING PRODUCT DEVELOPMENT
STABILITY TESTING DURING PRODUCT DEVELOPMENTAmruta Balekundri
 
Preformulation part 1- Preformulation- Crystal, Amorphous, Polymorphism, Pseu...
Preformulation part 1- Preformulation- Crystal, Amorphous, Polymorphism, Pseu...Preformulation part 1- Preformulation- Crystal, Amorphous, Polymorphism, Pseu...
Preformulation part 1- Preformulation- Crystal, Amorphous, Polymorphism, Pseu...vijaysrampur
 
Accelerated stability testing
Accelerated stability testingAccelerated stability testing
Accelerated stability testingGaurav Kr
 
Parameters in Preformulation Studies
Parameters in Preformulation StudiesParameters in Preformulation Studies
Parameters in Preformulation StudiesCognibrain Healthcare
 
Ich guidelines for stability studies 2
Ich guidelines for stability studies 2Ich guidelines for stability studies 2
Ich guidelines for stability studies 2priyanka odela
 
IPQC for capsule.
IPQC for capsule.IPQC for capsule.
IPQC for capsule.ganpat420
 
Stability studies of drugs
Stability studies of drugsStability studies of drugs
Stability studies of drugsPromila Sharan
 

What's hot (20)

Solid state drug stability
Solid state drug stabilitySolid state drug stability
Solid state drug stability
 
Accelerated stability studes
Accelerated stability studesAccelerated stability studes
Accelerated stability studes
 
Accelerated stability testing
Accelerated stability testingAccelerated stability testing
Accelerated stability testing
 
Ich guidelines Q1A(R2)
Ich guidelines Q1A(R2)Ich guidelines Q1A(R2)
Ich guidelines Q1A(R2)
 
Preformulation stability study
Preformulation stability studyPreformulation stability study
Preformulation stability study
 
Accelerated stability studies
Accelerated stability studiesAccelerated stability studies
Accelerated stability studies
 
Stability of Pharmaceuticals
Stability of PharmaceuticalsStability of Pharmaceuticals
Stability of Pharmaceuticals
 
Preformulation
PreformulationPreformulation
Preformulation
 
Stability protocols for different dosage forms by sachin jain
Stability protocols for different dosage forms by sachin jainStability protocols for different dosage forms by sachin jain
Stability protocols for different dosage forms by sachin jain
 
Stability and stability testing
Stability and stability testingStability and stability testing
Stability and stability testing
 
Stability testing and shelf life estimation
Stability testing and shelf life estimationStability testing and shelf life estimation
Stability testing and shelf life estimation
 
STABILITY TESTING DURING PRODUCT DEVELOPMENT
STABILITY TESTING DURING PRODUCT DEVELOPMENTSTABILITY TESTING DURING PRODUCT DEVELOPMENT
STABILITY TESTING DURING PRODUCT DEVELOPMENT
 
Preformulation part 1- Preformulation- Crystal, Amorphous, Polymorphism, Pseu...
Preformulation part 1- Preformulation- Crystal, Amorphous, Polymorphism, Pseu...Preformulation part 1- Preformulation- Crystal, Amorphous, Polymorphism, Pseu...
Preformulation part 1- Preformulation- Crystal, Amorphous, Polymorphism, Pseu...
 
Accelerated stability testing
Accelerated stability testingAccelerated stability testing
Accelerated stability testing
 
Parameters in Preformulation Studies
Parameters in Preformulation StudiesParameters in Preformulation Studies
Parameters in Preformulation Studies
 
PHOTOSTABILITY TESTING SEM I SEMINAR
PHOTOSTABILITY TESTING SEM I SEMINARPHOTOSTABILITY TESTING SEM I SEMINAR
PHOTOSTABILITY TESTING SEM I SEMINAR
 
Ich guidelines for stability studies 2
Ich guidelines for stability studies 2Ich guidelines for stability studies 2
Ich guidelines for stability studies 2
 
Ipqc tests for parentrals
Ipqc tests for parentralsIpqc tests for parentrals
Ipqc tests for parentrals
 
IPQC for capsule.
IPQC for capsule.IPQC for capsule.
IPQC for capsule.
 
Stability studies of drugs
Stability studies of drugsStability studies of drugs
Stability studies of drugs
 

Viewers also liked

The factors that affect the stability of complexes
The factors that affect the stability of complexes The factors that affect the stability of complexes
The factors that affect the stability of complexes Ernest Opoku
 
Physiochemical factors influencing formulaon
Physiochemical factors influencing formulaonPhysiochemical factors influencing formulaon
Physiochemical factors influencing formulaonVishnu Mashroowala
 
Nanotechnology in clinical trials final
Nanotechnology in clinical trials finalNanotechnology in clinical trials final
Nanotechnology in clinical trials finalBhaswat Chakraborty
 
Presentation2ghghl
Presentation2ghghlPresentation2ghghl
Presentation2ghghlMARYAM ANSAR
 
20111001 dansk journalistforbund copenhagen
20111001 dansk journalistforbund copenhagen20111001 dansk journalistforbund copenhagen
20111001 dansk journalistforbund copenhagenJuantxoCruz
 
Digital Marketing trends, SEO, Digital Marketing investment and ROI
Digital Marketing trends, SEO, Digital Marketing investment and ROIDigital Marketing trends, SEO, Digital Marketing investment and ROI
Digital Marketing trends, SEO, Digital Marketing investment and ROIIn Marketing We Trust
 
Ijarcet vol-2-issue-7-2384-2388
Ijarcet vol-2-issue-7-2384-2388Ijarcet vol-2-issue-7-2384-2388
Ijarcet vol-2-issue-7-2384-2388Editor IJARCET
 
Nanoparticle Gold in therapy and cosmetology
 Nanoparticle Gold in therapy and cosmetology Nanoparticle Gold in therapy and cosmetology
Nanoparticle Gold in therapy and cosmetologyguest49edce
 
effect of various environment and processing on stability of formulations
effect of various environment and processing on stability of formulationseffect of various environment and processing on stability of formulations
effect of various environment and processing on stability of formulationsManoj Kumar Tekuri
 
Targeting oral cancer using gold nanoparticles
Targeting oral cancer using gold nanoparticlesTargeting oral cancer using gold nanoparticles
Targeting oral cancer using gold nanoparticlesDr.Mohamad Ghazi
 

Viewers also liked (20)

Drug stability
Drug stabilityDrug stability
Drug stability
 
The factors that affect the stability of complexes
The factors that affect the stability of complexes The factors that affect the stability of complexes
The factors that affect the stability of complexes
 
Physiochemical factors influencing formulaon
Physiochemical factors influencing formulaonPhysiochemical factors influencing formulaon
Physiochemical factors influencing formulaon
 
Bppk ppt
Bppk pptBppk ppt
Bppk ppt
 
Stability
StabilityStability
Stability
 
Daniel
DanielDaniel
Daniel
 
Cancer nanotechnology
Cancer nanotechnologyCancer nanotechnology
Cancer nanotechnology
 
Nanotechnology in clinical trials final
Nanotechnology in clinical trials finalNanotechnology in clinical trials final
Nanotechnology in clinical trials final
 
Presentation2ghghl
Presentation2ghghlPresentation2ghghl
Presentation2ghghl
 
20111001 dansk journalistforbund copenhagen
20111001 dansk journalistforbund copenhagen20111001 dansk journalistforbund copenhagen
20111001 dansk journalistforbund copenhagen
 
Digital Marketing trends, SEO, Digital Marketing investment and ROI
Digital Marketing trends, SEO, Digital Marketing investment and ROIDigital Marketing trends, SEO, Digital Marketing investment and ROI
Digital Marketing trends, SEO, Digital Marketing investment and ROI
 
my ppt
my pptmy ppt
my ppt
 
Mpharm syallbas
Mpharm syallbasMpharm syallbas
Mpharm syallbas
 
Ijarcet vol-2-issue-7-2384-2388
Ijarcet vol-2-issue-7-2384-2388Ijarcet vol-2-issue-7-2384-2388
Ijarcet vol-2-issue-7-2384-2388
 
test
testtest
test
 
Solubilization by raghavendra kumar
Solubilization by raghavendra kumar Solubilization by raghavendra kumar
Solubilization by raghavendra kumar
 
Nanoparticle Gold in therapy and cosmetology
 Nanoparticle Gold in therapy and cosmetology Nanoparticle Gold in therapy and cosmetology
Nanoparticle Gold in therapy and cosmetology
 
effect of various environment and processing on stability of formulations
effect of various environment and processing on stability of formulationseffect of various environment and processing on stability of formulations
effect of various environment and processing on stability of formulations
 
Targeting oral cancer using gold nanoparticles
Targeting oral cancer using gold nanoparticlesTargeting oral cancer using gold nanoparticles
Targeting oral cancer using gold nanoparticles
 
Ppt On Data Interpretation For Cat
Ppt On Data Interpretation For CatPpt On Data Interpretation For Cat
Ppt On Data Interpretation For Cat
 

Similar to Stability Basic

Drug stability
Drug stabilityDrug stability
Drug stabilityDrAsimraza
 
Drug Stabily Assignment - Shivam Dubey
Drug Stabily Assignment - Shivam DubeyDrug Stabily Assignment - Shivam Dubey
Drug Stabily Assignment - Shivam DubeyMrHotmaster1
 
Kinetic principles in drug degradation
Kinetic principles in drug degradationKinetic principles in drug degradation
Kinetic principles in drug degradationTouheed Ovi
 
STABILITY STUDIES
STABILITY STUDIESSTABILITY STUDIES
STABILITY STUDIESTMU
 
Stability Testing.pptx ,M.PHARM,1ST year ,1st semester
Stability Testing.pptx ,M.PHARM,1ST year ,1st semesterStability Testing.pptx ,M.PHARM,1ST year ,1st semester
Stability Testing.pptx ,M.PHARM,1ST year ,1st semesterManshiRana2
 
Asean stability guideline (version 6.0)
Asean stability guideline (version 6.0)Asean stability guideline (version 6.0)
Asean stability guideline (version 6.0)Pradeep Kumar
 
Stability_Considerations_In_Formulation_Development.ppt
Stability_Considerations_In_Formulation_Development.pptStability_Considerations_In_Formulation_Development.ppt
Stability_Considerations_In_Formulation_Development.pptRavi Kumar G
 
Solid state stability and shelf-life assignment, Stability protocols,reports ...
Solid state stability and shelf-life assignment, Stability protocols,reports ...Solid state stability and shelf-life assignment, Stability protocols,reports ...
Solid state stability and shelf-life assignment, Stability protocols,reports ...Durga Bhavani
 
Formulation development of pharmaceutical drug
Formulation development of pharmaceutical drugFormulation development of pharmaceutical drug
Formulation development of pharmaceutical drugSriramPraveen5
 
ICH guidelines for stability studies
ICH guidelines for stability studiesICH guidelines for stability studies
ICH guidelines for stability studiessurabhikonjeti
 
The Essentials of USP chapter 51 antimicrobial effectiveness testing
The Essentials of USP chapter 51 antimicrobial effectiveness testingThe Essentials of USP chapter 51 antimicrobial effectiveness testing
The Essentials of USP chapter 51 antimicrobial effectiveness testingGuide_Consulting
 

Similar to Stability Basic (20)

Drug stability
Drug stabilityDrug stability
Drug stability
 
Drug Stabily Assignment - Shivam Dubey
Drug Stabily Assignment - Shivam DubeyDrug Stabily Assignment - Shivam Dubey
Drug Stabily Assignment - Shivam Dubey
 
Kinetic principles in drug degradation
Kinetic principles in drug degradationKinetic principles in drug degradation
Kinetic principles in drug degradation
 
5.1. DRUG STABILITY.pdf
5.1. DRUG STABILITY.pdf5.1. DRUG STABILITY.pdf
5.1. DRUG STABILITY.pdf
 
STABILITY STUDIES
STABILITY STUDIESSTABILITY STUDIES
STABILITY STUDIES
 
Stability Testing.pptx ,M.PHARM,1ST year ,1st semester
Stability Testing.pptx ,M.PHARM,1ST year ,1st semesterStability Testing.pptx ,M.PHARM,1ST year ,1st semester
Stability Testing.pptx ,M.PHARM,1ST year ,1st semester
 
stability ASEAN guidelines
stability ASEAN guidelinesstability ASEAN guidelines
stability ASEAN guidelines
 
Asean stability guideline (version 6.0)
Asean stability guideline (version 6.0)Asean stability guideline (version 6.0)
Asean stability guideline (version 6.0)
 
Stability_Considerations_In_Formulation_Development.ppt
Stability_Considerations_In_Formulation_Development.pptStability_Considerations_In_Formulation_Development.ppt
Stability_Considerations_In_Formulation_Development.ppt
 
Preformulation
PreformulationPreformulation
Preformulation
 
Solid state stability and shelf-life assignment, Stability protocols,reports ...
Solid state stability and shelf-life assignment, Stability protocols,reports ...Solid state stability and shelf-life assignment, Stability protocols,reports ...
Solid state stability and shelf-life assignment, Stability protocols,reports ...
 
Perbandingan uji stabilitas
Perbandingan uji stabilitasPerbandingan uji stabilitas
Perbandingan uji stabilitas
 
Formulation development of pharmaceutical drug
Formulation development of pharmaceutical drugFormulation development of pharmaceutical drug
Formulation development of pharmaceutical drug
 
Packing techno
Packing technoPacking techno
Packing techno
 
ICH Guidelines
ICH GuidelinesICH Guidelines
ICH Guidelines
 
in vivo in vitro
in vivo in vitroin vivo in vitro
in vivo in vitro
 
ICH guidelines for stability studies
ICH guidelines for stability studiesICH guidelines for stability studies
ICH guidelines for stability studies
 
The Essentials of USP chapter 51 antimicrobial effectiveness testing
The Essentials of USP chapter 51 antimicrobial effectiveness testingThe Essentials of USP chapter 51 antimicrobial effectiveness testing
The Essentials of USP chapter 51 antimicrobial effectiveness testing
 
Stability studies of drugs
Stability studies of drugsStability studies of drugs
Stability studies of drugs
 
06Purity & Impurity(1).ppt
06Purity & Impurity(1).ppt06Purity & Impurity(1).ppt
06Purity & Impurity(1).ppt
 

Recently uploaded

5 charts on South Africa as a source country for international student recrui...
5 charts on South Africa as a source country for international student recrui...5 charts on South Africa as a source country for international student recrui...
5 charts on South Africa as a source country for international student recrui...CaraSkikne1
 
Ultra structure and life cycle of Plasmodium.pptx
Ultra structure and life cycle of Plasmodium.pptxUltra structure and life cycle of Plasmodium.pptx
Ultra structure and life cycle of Plasmodium.pptxDr. Asif Anas
 
The Stolen Bacillus by Herbert George Wells
The Stolen Bacillus by Herbert George WellsThe Stolen Bacillus by Herbert George Wells
The Stolen Bacillus by Herbert George WellsEugene Lysak
 
How to Make a Field read-only in Odoo 17
How to Make a Field read-only in Odoo 17How to Make a Field read-only in Odoo 17
How to Make a Field read-only in Odoo 17Celine George
 
Easter in the USA presentation by Chloe.
Easter in the USA presentation by Chloe.Easter in the USA presentation by Chloe.
Easter in the USA presentation by Chloe.EnglishCEIPdeSigeiro
 
Quality Assurance_GOOD LABORATORY PRACTICE
Quality Assurance_GOOD LABORATORY PRACTICEQuality Assurance_GOOD LABORATORY PRACTICE
Quality Assurance_GOOD LABORATORY PRACTICESayali Powar
 
PISA-VET launch_El Iza Mohamedou_19 March 2024.pptx
PISA-VET launch_El Iza Mohamedou_19 March 2024.pptxPISA-VET launch_El Iza Mohamedou_19 March 2024.pptx
PISA-VET launch_El Iza Mohamedou_19 March 2024.pptxEduSkills OECD
 
Maximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdf
Maximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdfMaximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdf
Maximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdfTechSoup
 
3.21.24 The Origins of Black Power.pptx
3.21.24  The Origins of Black Power.pptx3.21.24  The Origins of Black Power.pptx
3.21.24 The Origins of Black Power.pptxmary850239
 
In - Vivo and In - Vitro Correlation.pptx
In - Vivo and In - Vitro Correlation.pptxIn - Vivo and In - Vitro Correlation.pptx
In - Vivo and In - Vitro Correlation.pptxAditiChauhan701637
 
Clinical Pharmacy Introduction to Clinical Pharmacy, Concept of clinical pptx
Clinical Pharmacy  Introduction to Clinical Pharmacy, Concept of clinical pptxClinical Pharmacy  Introduction to Clinical Pharmacy, Concept of clinical pptx
Clinical Pharmacy Introduction to Clinical Pharmacy, Concept of clinical pptxraviapr7
 
Patient Counselling. Definition of patient counseling; steps involved in pati...
Patient Counselling. Definition of patient counseling; steps involved in pati...Patient Counselling. Definition of patient counseling; steps involved in pati...
Patient Counselling. Definition of patient counseling; steps involved in pati...raviapr7
 
Human-AI Co-Creation of Worked Examples for Programming Classes
Human-AI Co-Creation of Worked Examples for Programming ClassesHuman-AI Co-Creation of Worked Examples for Programming Classes
Human-AI Co-Creation of Worked Examples for Programming ClassesMohammad Hassany
 
General views of Histopathology and step
General views of Histopathology and stepGeneral views of Histopathology and step
General views of Histopathology and stepobaje godwin sunday
 
CapTechU Doctoral Presentation -March 2024 slides.pptx
CapTechU Doctoral Presentation -March 2024 slides.pptxCapTechU Doctoral Presentation -March 2024 slides.pptx
CapTechU Doctoral Presentation -March 2024 slides.pptxCapitolTechU
 
M-2- General Reactions of amino acids.pptx
M-2- General Reactions of amino acids.pptxM-2- General Reactions of amino acids.pptx
M-2- General Reactions of amino acids.pptxDr. Santhosh Kumar. N
 
Patterns of Written Texts Across Disciplines.pptx
Patterns of Written Texts Across Disciplines.pptxPatterns of Written Texts Across Disciplines.pptx
Patterns of Written Texts Across Disciplines.pptxMYDA ANGELICA SUAN
 
Drug Information Services- DIC and Sources.
Drug Information Services- DIC and Sources.Drug Information Services- DIC and Sources.
Drug Information Services- DIC and Sources.raviapr7
 
How to Use api.constrains ( ) in Odoo 17
How to Use api.constrains ( ) in Odoo 17How to Use api.constrains ( ) in Odoo 17
How to Use api.constrains ( ) in Odoo 17Celine George
 

Recently uploaded (20)

5 charts on South Africa as a source country for international student recrui...
5 charts on South Africa as a source country for international student recrui...5 charts on South Africa as a source country for international student recrui...
5 charts on South Africa as a source country for international student recrui...
 
Ultra structure and life cycle of Plasmodium.pptx
Ultra structure and life cycle of Plasmodium.pptxUltra structure and life cycle of Plasmodium.pptx
Ultra structure and life cycle of Plasmodium.pptx
 
The Stolen Bacillus by Herbert George Wells
The Stolen Bacillus by Herbert George WellsThe Stolen Bacillus by Herbert George Wells
The Stolen Bacillus by Herbert George Wells
 
How to Make a Field read-only in Odoo 17
How to Make a Field read-only in Odoo 17How to Make a Field read-only in Odoo 17
How to Make a Field read-only in Odoo 17
 
Easter in the USA presentation by Chloe.
Easter in the USA presentation by Chloe.Easter in the USA presentation by Chloe.
Easter in the USA presentation by Chloe.
 
Quality Assurance_GOOD LABORATORY PRACTICE
Quality Assurance_GOOD LABORATORY PRACTICEQuality Assurance_GOOD LABORATORY PRACTICE
Quality Assurance_GOOD LABORATORY PRACTICE
 
PISA-VET launch_El Iza Mohamedou_19 March 2024.pptx
PISA-VET launch_El Iza Mohamedou_19 March 2024.pptxPISA-VET launch_El Iza Mohamedou_19 March 2024.pptx
PISA-VET launch_El Iza Mohamedou_19 March 2024.pptx
 
Maximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdf
Maximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdfMaximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdf
Maximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdf
 
3.21.24 The Origins of Black Power.pptx
3.21.24  The Origins of Black Power.pptx3.21.24  The Origins of Black Power.pptx
3.21.24 The Origins of Black Power.pptx
 
In - Vivo and In - Vitro Correlation.pptx
In - Vivo and In - Vitro Correlation.pptxIn - Vivo and In - Vitro Correlation.pptx
In - Vivo and In - Vitro Correlation.pptx
 
Clinical Pharmacy Introduction to Clinical Pharmacy, Concept of clinical pptx
Clinical Pharmacy  Introduction to Clinical Pharmacy, Concept of clinical pptxClinical Pharmacy  Introduction to Clinical Pharmacy, Concept of clinical pptx
Clinical Pharmacy Introduction to Clinical Pharmacy, Concept of clinical pptx
 
Patient Counselling. Definition of patient counseling; steps involved in pati...
Patient Counselling. Definition of patient counseling; steps involved in pati...Patient Counselling. Definition of patient counseling; steps involved in pati...
Patient Counselling. Definition of patient counseling; steps involved in pati...
 
Human-AI Co-Creation of Worked Examples for Programming Classes
Human-AI Co-Creation of Worked Examples for Programming ClassesHuman-AI Co-Creation of Worked Examples for Programming Classes
Human-AI Co-Creation of Worked Examples for Programming Classes
 
General views of Histopathology and step
General views of Histopathology and stepGeneral views of Histopathology and step
General views of Histopathology and step
 
Personal Resilience in Project Management 2 - TV Edit 1a.pdf
Personal Resilience in Project Management 2 - TV Edit 1a.pdfPersonal Resilience in Project Management 2 - TV Edit 1a.pdf
Personal Resilience in Project Management 2 - TV Edit 1a.pdf
 
CapTechU Doctoral Presentation -March 2024 slides.pptx
CapTechU Doctoral Presentation -March 2024 slides.pptxCapTechU Doctoral Presentation -March 2024 slides.pptx
CapTechU Doctoral Presentation -March 2024 slides.pptx
 
M-2- General Reactions of amino acids.pptx
M-2- General Reactions of amino acids.pptxM-2- General Reactions of amino acids.pptx
M-2- General Reactions of amino acids.pptx
 
Patterns of Written Texts Across Disciplines.pptx
Patterns of Written Texts Across Disciplines.pptxPatterns of Written Texts Across Disciplines.pptx
Patterns of Written Texts Across Disciplines.pptx
 
Drug Information Services- DIC and Sources.
Drug Information Services- DIC and Sources.Drug Information Services- DIC and Sources.
Drug Information Services- DIC and Sources.
 
How to Use api.constrains ( ) in Odoo 17
How to Use api.constrains ( ) in Odoo 17How to Use api.constrains ( ) in Odoo 17
How to Use api.constrains ( ) in Odoo 17
 

Stability Basic

  • 1. Why stability studies ?  Stability is an essential quality attribute for drug products.  If there is any functionally relevant quality attribute of a drug product that changes with time, this evaluation checked by pharmaceutical scientists and regulators who quantify drug product stability and shelf life.  The rate at which drug products degrade varies dramatically. e.g. radiopharmaceutical products  Since the evaluation of the stability of drug product is highly specialized and esoteric nature.  Drug stability concerns about drug product safety , efficacy, and quality, found it to appropriate.  Stability studies is done through the regulatory agencies such as the FDA and the HPB (health protection branch ) Functional changes in dosage forms with time • It may be related to changes in chemical or physical properties of drug and excipients, coating materials etc. or it may be related to complex interaction between components of dosage form. • Chemical stability can be assessed similar to above for drugs and excipients. • For assessments of physical changes to dosage form changes specific to each dosage form should be evaluated. Changes in Mechanical strength • Storage in humid condition leads to moisture adsorption and so decreased mechanical strength of tablet in blister packages. • The change in mechanical strength can be described as a function of moisture sensitivity, moisture permeability, and humidity condition which is used for prediction of storage period. Changes in drug dissolution from tablets and capsule • Dissolution of a drug substance is very important characteristic for bioavailability and it changes on storage • Changes in melting time of suppositories • Changes in release rate from polymeric matrix dosage for , including microspheres • Drug leakage from liposomes • Aggregation in emulsion • Discoloration • Moisture adsorption Effect of changes on drug stability of drug products • Packaging play an important role in quality maintenance and the resistance of packaging material to moisture and light can significantly affect the stability of products
  • 2. Protection from light can be achieved using primary and secondary packaging made up of light resistant material. • Incorporating oxygen adsorbents such iron powder can reduce the effect of oxygen.3 Relevant guidelines  ICH Q1A(R2): Stability Testing of New Drug Substances and Products  ICH Q1B: Photostability Testing of New Drug Substances and Products  ICH Q1C: Stability Testing of New Dosage Forms  ICH Q5C: Stability Testing of Biotechnological/  Biological Products  ICH Q1D: Bracketing and Matrixing Designs  ICH Q1E: Stability Data Evaluation  ICH Q1F: Stability Data Package for Zones III and IV Potential adverse effects of instability in pharmaceutical products There is a various mechanisms by which drug products may degrade.  Loss of active  Increase in concentration of active  Alteration in bioavailability  Loss of content uniformity  Decline of microbiological status  Loss of content uniformity  Decline of microbiological status  Loss of pharmaceutical elegance and patient acceptability  Formation of toxic degradation products  Loss of package integrity  Reduction of label quality  Modification of any factor of functional relevance. 1 1. Loss of active  loss of drug is main significance in the stability studies of many pharmaceutical products.  However, it is certainly true that for many products loss of potency is of major importance.  we regard any product that contains less than 90% of label claim of drug as being of unacceptable quality.  The potency of product stored at the appropriate temperature (250 C for products to be labelled “store at controlled room temperature”) 2. Increase in concentration of active  For some products, loss of vehicle can result in an increase in the concentration of active drug .  For e.g. lidocaine gels exhibit this behavior
  • 3.  Perfusion bags sometimes allow solvent to escape and evaporate so that the product within the bag shows an increase in concentration. 3. Alteration in bioavailability  Bioavailability of drug products is a subject of great importance to those concerned with drug product quality .  If the rate or extent of absorption that characterizes a product changes on storage, then this of course, a stability problem.  In particular, if any changes of dissolution test data with time it would effect bioavailability 4. Loss of content uniformity  Suspensions are the drug delivery systems most likely to show a loss of content uniformity as function of time.  For such systems, determination of ease of redispersion or sedimentation volume may therefore be included in a stability protocol 5. Decline of microbiological status  Basically, there are some possible ways in which the microbiological status of a pharmaceutical product can change significantly with time.  The microorganism present in the product at the time of manufacture may reproduce and thus increase the number of viable organisms.  Thus a product that, when assayed for total bioburden at the time of manufacture, is within limits, then tested after 6 months storage, exceed the maximum permitted bioburden is maximum. 6. Loss of pharmaceutical elegance and patient acceptability  It includes any aspect of the product that might suggest that the product is somehow substandard or variable.  For example some drugs that contain amino functional groups, when made into direct compression tablets that contain spray-dried lactose, which results the some slight brown speckling on the surface of the tablet .  This is due to the interaction of the drug with a minor component in the lactose  Analysis of the tablets might reveal no loss potency or change in dissolution, but no reputable manufacture will market tablets because of its look.  It is important point about drug products is that attributes such as appearance, taste, and smell should be reproducible and not so any significant batch to batch variation . 7. Formation of toxic degradation products  If a drug degrades to a molecular species that is toxic, there must be special attention given to the quantity of such a species found in the product during its shelf life.  The classic example is epianhydrotetracycline from tetracycline. 8. Loss of package integrity  Change in the package integrity during storage or distribution can be a stability problem that may require careful monitoring.  For example, if a plastic screw cap loses back-off –torque, the possibility of chemical or microbiological hazard may be significantly increased.
  • 4. 9. Reduction of label quality  The label of a drug product must be regarded as an essential element of the product.  It provides information on identity, use, and safety. Thus if any aspect of the label deteriorates with time, this can be a serious stability problem.  For example, if the plasticizer in a plastic bottle migrates into the label and causes the ink to run and thus effects legibility, this is major problem. 10. Modification of any factor of functional relevance  If there is any change of any functionality relevant attribute of a drug product that adversely affects safety, efficacy, or patient acceptability.  For example, when some transdermal patches were first introduce into the US, a problem of adhesion ageing is observed .  Freshly prepared patches show excellent skin adhesion, while it stored in room temperature for weeks or months show loss of adhesion.  Thus in use the patches had a tendency to fall off the patient’s skin 1. Reasons for stability testing  Our concerns for patients welfare  To protect the reputation of the producer  Requirements of regulatory agencies  To provide a database that may be of value in the formation of other products Modes of degradation Chemical  Chemical degradation is like solvolysis and oxidation.  Our knowledge of kinetics can be of material assistance in dealing with chemical degradation. Physical  Physical degradation can be caused by a range of factors such as freezing, thawing, or shearing  The physical methods that could be used in evaluation of tablet friability, suspension redispersibilty, or injection syringeability Biological  In north America, Japan, and western Europe it is microbiological stability problems.  However, in some parts of the rats, ants, and the non microbiological factors can be responsible for stability problems Stability indicating method General tests  Appearance  Assays/potency  Sterility /container integrity  Moisture  Degradation products
  • 5. Product specific tests  Aggregation (proteins)  Biological activity (proteins) Dosage form specific tests  Dissolution/release rate (tablets/patches)  Leachable/extractable (injections)  Particle size and turbidity( injection)  Preservatives The essential elements of stability program  Commitment of the organization to quality  Firm grasp of underlying scientific theory  Up-to-date knowledge of all relevant polices of regulatory agencies and applicable pharmacopoeial standards  Effective communication between R&D, production, QC/QA, complaints, and regulatory affairs  Understanding of the limitations of the analytical methods used in the stability program  Careful monitoring of the stability budget  Managerial skills to coordinate and optimize the program.1 What is kinetics?  kinetics is a rate of reaction which takes place in a particular compound.  It may be change in parent compound either physical or chemical.  Physical change include biotransformation.  Chemical change include degradation Application of kinetics in stability  To understand the mechanism of what kind of change.  To estimate the degradation time.  Some time half life or shelf life may be determine by the kinetic.  For prediction of process mean by keeping the compound, what kind of change and how much time will be taken for that change will be estimated.3 Routes by which pharmaceuticals degrade a. Chemical degradative routes 1. Solvolysis 2. Oxidation 3. Photolysis 4. Dehydration 5. Racemization 6. Incompatibilities b. Physical degradative routes 1. Vaporization 2. Aging 3. Adsorption
  • 6. 4. Physical instability in Heterogeneous Systems Rate of reaction  Reaction can be of two type 1. Homogeneous this is uniform process and taking place in single phase. 2. Heterogeneous taking place in more than two phase. • Eg. decomposition of drug in suspension and enzyme catalyzed reaction. • Rate of reaction depended upon concentration of the reactant. • Chemical kinetics deals with the experimental determination of reaction rates from which rate laws and rate constants are derived. • Relatively simple rate laws exist for zero order reactions (for which reaction rates are independent of concentration), first order reactions, and second order reactions, and can be derived for others. • The activation energy for a reaction is experimentally determined through the Arrhenius equation and the Eyring equation.  The main factors that influence the reaction rate include: 1. the physical state of the reactants, 2. the concentrations of the reactants, 3. the temperature at which the reaction occurs, and 4. whether or not any catalysts are present in the reaction. Factors affecting rate of reaction 1. Nature of the Reactants  Depending upon what substances are reacting, the time varies.  Acid reactions, the formation of salts, and ion exchange are fast reactions.  When covalent bond formation takes place between the molecules and when large molecules are formed, the reactions tend to be very slow. 2. Physical State  The physical state (solid, liquid, or gas) of a reactant is also an important factor of the rate of change.  Reaction can only occur at their area of contact, in the case of a liquid and a gas, at the surface of the liquid.  Vigorous shaking and stirring may be needed to bring the reaction to completion. This means that the more finely divided a solid or liquid reactant, the greater its surface area per unit volume, and the more contact it makes with the other reactant, thus the faster the reaction. 3. Concentration  As the concentration of the reactants increases, the frequency of the molecules colliding increases, striking each other more frequently by being in closer contact at any given point in time.  By increasing the amount of one or more of the reactants you cause these collisions to happen more often, increasing the reaction rate.
  • 7. 4. Temperature  Temperature usually has a major effect on the rate of a chemical reaction.  Collision frequency is greater at higher temperatures, contributes very small proportion to the increase in rate of reaction.  The important factor is reactant molecule should have reactive energy higher then activation energy ( E>Ea ) to react. 5. Catalysts  A catalyst is a substance that accelerates the rate of a chemical reaction but remains chemically unchanged afterwards.  The catalyst increases rate reaction by providing a different reaction mechanism to occur with a lower activation energy.  Proteins that act as catalysts in biochemical reactions are called enzymes.5  The manner in which the concentration of drug (or reactants) influences the rate of reaction or process is called as the order of reaction.  If C is the conc. of drug A, the rate of decrease in C of drug A as it is changed to B can be expressed as a function of time t. dC/dt = -K Cn dC/dt = -K Cn _______(1) K= rate constant n= order of reaction If n = 0 than zero order reaction, If n =1 than first order reaction
  • 8. dC/dt = term  Change in conc. (dC) with respect to time (dt) called as rate of reaction Zero order kinetics (constant rate processes)  if n = 0 than, dC/dt = -K0 C0 = -K0 ____(2) K0 = zero order rate constant  It is a reaction whose rate is independent of the concentration of drug undergoing reaction, so the rate can’t be increased further by increasing the concentration of reactants.  Rearrangement of equation (2) yields: dC = -K0 dt  Integration of above equation: C – C0 = -K0 t C = C0 - K0t ______(3) C = conc. of drug at time t C0 =conc. of drug at time t = 0  Eq. 3 states that the conc. of reactant decreases linearly with time.  A plot of C vs. t yields straight line having slope –K0 and y-intercept C0 C0 Steady drug loss Slope = -K0 C dC/dt time time Zero order half life  It is the time period req. for the conc. of drug to decrease by one-half.  When t = t1/2 and C = C0 /2, then eq. 3 becomes C0/2 = C0 – K0 t1/2  Solving above eq.
  • 9. t1/2 = C0/2K0 = 0.5C0/K0 ______(4)  Eq. shows that t1/2 of a zero order process is not constant but proportional to the initial conc. of drug C0 and inversely proportional to the zero order rate constant K0. 4 First order kinetics (Linear kinetics)  If n = 1 then eq. 1 becomes dC/dt = -K C _____(5) K = first order rate constant in time-1  Rate of reaction is directly proportional to the conc. of drug undergoing reaction, so greater the conc. , faster the reaction. Slope = -K dC/dt C  Rearrangement of eq. 5 yields dC/C = -K dt  Integration of above eq. gives. ln C = ln C0 – Kt _____(6)  This eq. can also be written as exponential form as: C = C0 e-Kt e = natural log base  First order process is also known as monoexponential rate process and characterized by logarithmic or exponential kinetics.  Since ln = 2.303 log, eq. 6 can be written as log C = log C0 – (Kt/2.303) _______(7)  A semilogarithmic plot of eq. 7 gives a straight line with slope = -K/2.303 and y- intercept = log C0
  • 10. Log C0 log C Slope = -K/2.303 t1/2 time Semilog graph of first order kinetics First order half life  put the value of C = C0/2 at t = t1/2 in eq.7 and solving it t1/2 = 0.693/K _____(8)  It indicate that half life of first order reaction is a constant and independent of initial drug conc.  Hydrolytic reaction of many drugs follows second order kinetics but after excess amt. of water is added then conc. remain constant throughout the process. It called apparent first order kinetics. SECOND ORDER KINETICS  If a drug substance A react with a second substance B then:  A+B=C  Then the rate eq. is  -d[A]/dt = k [A][B] MIXED ORDER KINETICS (NONLINEAR KINETICS)  In some cases, the kinetics of a pharmacokinetic process change from predominantly first order to predominantly zero order with increasing dose or chronic medication.  A mixture of both first order and zero order kinetics is called as mixed order kinetics. Also known as nonlinear kinetics or dose dependent kinetics.  Nonlinearity observed in certain drugs like; vitamin C, naproxen, riboflavin. The kinetics of such capacity limited processes can be described by the Michaelis- Menten kinetics.  Michaelis Menten Equation  Mixed order kinetics is best described by this equation:
  • 11. -dC/dt = Vmax C/(Km + C) _____(9)  -dC/dt = rate of decline of drug concentration with time,  Vmax = theoretical maximum rate of the process,  Km = Michaelis constant. 4 Factors affecting stability of drug and dosage form • These factors can be broadly classified into 3 types depending on their effect on different type of stability which are as follows: • 1) Chemical factors • 2) Physical factors • 3) Biological factors 1) Chemical factors Various ways of chemical degradation includes • hydrolysis • dehydration • isomerization & racemization • decarboxylation & elimination • oxidation • photo degradation • drug – excipients & drug – drug interactions such as a) Reaction of bisulfite, an oxidant b) Reaction of amines with reducing sugars3 A) THE ROLE OF MOLECULAR STRUCTURE • It has been noted earlier that molecular structure of drug substance determines its degradation mechanisms and that substituents around the reaction centre can strongly influence its reactivity. • Example: drug sub. having an electron withdrawing group close to an ester bond will probably exhibit a higher propensity nucleophilic attack by hydroxide ion than will a similar ester without that functional group • Steric factors can be significant for many chemical reactions. B) TEMPERATURE • It is one of the primary factors affecting drug stability. • The rate constant/temperature relationship has traditionally been described by the Arhenius equation, k = A exp (-Ea/RT) • where Ea = activation energy A = frequency factor
  • 12. Arhenius equation has traditionally been used to describe the temperature dependency for various chemical reaction by regarding A and Ea as independent of temperature. • Temperature is obviously an important parameter because most reactions proceed faster at elevated temperatures than at lower temperatures. • The terms Ea and ∆H are a measure of how sensitive the degradation rate of a drug is to temperature changes. • Quantitation of the temperature Dependency of degradation rate constants can be done by 3 ways: 1) Prediction of Degradation rate by Linear Regression Analysis of the Arhenius Equation 2) Prediction of degradation rate by Nonlinear Regression Analysis of the Arhenius Equation. 3) Nonisothermal Prediction of Degradation Rate C) pH AND pH RATE PROFILES • Second most important parameter • The effect of pH on degradation rate can be explained by the catalytic effects that hydronium or hydroxide ions can have on various chemical reactions. • If critical path in a reaction involves a proton transfer or abstraction step, other acids and bases present in solution can affect the rate of reaction. • For ionizable drugs, the fraction of drug present in any particular form will depend on the pH of the solution, • So, if the reactivity of the drug depends on its form, its reactivity will be pH- dependent. • A reaction in which hydronium ion, hydroxide ion, and water catalysis are observed can be described by Kobs = kH+ aH+ + KH2O + KoH- aOH- Where Kobs = sum of specific rate constants aH+ = activities of hydronium ion aOH- =activities of hydroxide ion This equation is for the case when drug is neutral in the pH range of study.i.e.where the ionization of drug does not have to take into account D) BUFFER • These buffer species, like H+ and OH-, participates in formation of break down of activated complexes of various reaction and determine their reaction rate. • These catalytic species are referred to as general acid-base catalysts
  • 13. Studies with phosphate buffer indicates that it enhance the degradation of various drug substances such as carbenicillin etc. • In addition to acting as proto donor or accepter, buffer species can also act as Lewis acid and base through nucleophilic or electrophilic mechanisms. E) IONIC STRENGTH-PRIMARY SALT EFFECT • For drug degradation involving reactions with or between ionic species, the rate is affected by the presence of other ionic species such as salts of NaCl. • Ionic strength affects the observed degradation rate constants, k, by its effect on the reactivity coefficients, f. • Ionic strength µ is described by µ = ½ ε Ci Zi2 Where Ci = conc. Of ionic species I Zi =its electric change • As ionic strength increases, the rate of reaction between ions of opposite charge decreases and the rate of reaction between ions of similar charges increases. • So, studying the effect of ionic strength can help our understanding of the possible charges of the species involved in the degradation. F) OXYGEN • Drugs can be affected by the availability of oxygen. • Some photo degradation reactions involve photo oxidative mechanisms that are dependent on conc. of oxygen. • Oxygen participates as reactant and also alters the degradation rate • Oxygen exists in various states such ground state triplate oxygen, etc. • Singlate oxygen is highly oxidizing and capable of attacking olfenic bonds. • Super oxide species is a mild reductant while hydrogen peroxide is fairly specific oxidant. G) LIGHT • The number and wavelength of incident photons affect the photo degradation rate of drugs. • It is not easy to study the effect of light quantitatively as the wavelength dependence of degradation varies among drug substances and because light sources have different spectral distributions. • Photo degradation for drug strongly dependence on the spectral properties of the drug substances and the spectral distribution of the light source.
  • 14. H) Crystalline state and polymorphism in solid drugs • Drugs in the crystalline state have lower ground state free energy and exhibit higher ∆G and so, slow reactivity. • Many drug substances exhibit polymorphism-each crystalline state has a different ground state free energy level and a different chemical reactivity. • The stability of drugs in their amorphous form is generally lower than that of drugs • In their crystalline form due to higher free energy level of amorphous form. • Decreased chemical stability of solid drugs brought about by mechanical stresses such as grinding is said to be due to change in crystalline state -eg: grinding of aspirin increased degradation rate in suspension form.3 I) MOISTURE AND HUMIDITY • Drug degradation in heterogeneous system such as solid and semisolid states is affected by moisture. • Moisture plays important role in catalyzing chemical degradation: 1) Water participates in the drug degradation process itself as a reactant, leading to hydrolysis; hydration etc. Here degradation rate is directly affected by the concentration of water, hydronium ion, hydroxide ion. 2) Water absorbs onto the drug surface and forms a moisture-sorbed layer in which the drug is dissolved and degraded. • Water adsorption may also change the physical state of the drugs, thereby affecting their reactivity. J) EXCIPIENTS • The role that excipients play in drug stability has been extensively reported-e.g.: accelerating the effect of talc on hydrolysis of thiamine hydrochloride, the accelerating effect of magnesium stearate on tablet containing amines and lactose etc. • Additional informations include reports on compatibility and incompatibility of drugs. • Excipients can affect drug stability via various mechanisms. • The most obvious examples are those in which the excipients participate directly in degradation as reactants. • Other mechanisms: 1) Effect of moisture present in excipients 2) The effect pH changes caused by excipients: 3) Effect of surfactants
  • 15. K) MISCELLANEOUS FACTORS • Effect of γ irradiation: − not a common variable − employed for sterilization of pharmaceuticals e.g. decreased activity of insulin after γ irradiations • Components of pharmaceuticals exist in various physical states like amorphous, hydrated and solvated form. • The rate of conversion will depend on chemical potential corresponding to the free energy difference between 2 states. The various physical changes that can occur in drugs and excipients are as follow: 1) Crystallization of amorphous drugs • Attempts are made to formulate poorly soluble drugs into amorphous form as it has higher solubility that of crystalline state. • But amorphous form change to crystalline state duo low free energy of it. • So crystallization of amorphous drug may occur on long storage leading to change in release character of drugs and so in its effect. • E.g. :amorphous nifedipine co precipitated with polyvinylpyrrolidone, undergoes partial crystallization under high humidity conditions resulted altered dissolution and solubility 2) Vapor phase transfers including sublimation • Pharmaceuticals containing components that easily sublime may undergo changes in drug content due to sublimation of it. • E.g. nitroglycerine , which is liquid with significant vapor pressure,sublinguel tablet exhibited significant changes in drug content during storage due to inter tablet migration through the vapor phase 3) Moisture Adsorption • generally observed with solid pharmaceuticals • It leads changes in physical properties such as appearance and dissolution rate. • Moisture adsorption is governed by the physical properties of drug and excipients. • E.g. :adsorption moisture by aspirin crystals enhanced by addition of hydrophilic excipients3 references 1. Drug stability: principles and practices, 3rd edition, by Jens T. Carstensen and C. T. Rhodes
  • 16. 2. Modern pharmaceutics, 4th edition, by Gilbert S. Banker and Christopher T. Rhodes 3. Stability of drugs and dosage forms by Sumie Yoshioka and Valentino J. Stella; Springer Publication 4. The theory & practice of Industrial Pharmacy by Leon Lachman, 3rd edition 5. www.wikipedia.com